VEC.L - Vectura Group plc

LSE - LSE Delayed price. Currency in GBp
80.95
+1.75 (+2.21%)
At close: 5:07PM BST
Stock chart is not supported by your current browser
Previous close79.20
Open79.45
Bid0.00 x 382500
Ask110.00 x 252100
Day's range78.90 - 81.00
52-week range68.00 - 127.20
Volume452,331
Avg. volume3,182,126
Market cap537.041M
Beta0.62
PE ratio (TTM)N/A
EPS (TTM)-12.60
Earnings date11 Sep 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est133.00
  • Reuters4 months ago

    Vectura posts wider 2017 loss, revenue rise

    The company, which bought rival SkyePharma for 441 million pounds in June 2016, said pretax loss stood at 102.2 million pounds against analysts' expectations of a loss of 88.7 million pounds, according to Thomson Reuters data. The asthma inhaler-maker said total royalties fell to 52.6 million pounds from 74.5 million pounds a year earlier. The company derives 35 percent of its revenue from royalties.

  • Reuters - UK Focus4 months ago

    BUZZ-Hikma, Vectura: Shares down, generic Advair delayed again

    ** Shares of Hikma Pharmaceutical fall 6 pct at open, now down 2 pct, with Vectura down 5.3 pct ** Hikma fails to find quick resolution in dispute with U.S. FDA over plans to launch a generic copy of GlaxoSmithKline's ...

  • Reuters4 months ago

    GSK wins new reprieve as Hikma's generic Advair delayed again

    The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.

  • Reuters - UK Focus4 months ago

    GSK wins new reprieve as Hikma's generic Advair delayed again

    GlaxoSmithKline (Other OTC: GLAXF - news) has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura, said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well.

  • Reuters5 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters - UK Focus5 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline (Other OTC: GLAXF - news) has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • Reuters - UK Focus8 months ago

    Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

    Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time. The dispute between the Jordan-based firm, its partner Vectura and the U.S FDA delays any eventual approval of the generic version of the drug. Shares (Berlin: DI6.BE - news) of Hikma were down 5.5 percent at market open, while Vectura shares were down about 10 percent.

  • Reuters8 months ago

    Hikma, Vectura in dispute with FDA over generic Advair

    LONDON (Reuters) - Hikma (HIK.L) and its partner Vectura (VEC.L) are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's (GSK.L) popular lung ...

  • Reuters - UK Focus9 months ago

    Vectura asthma inhaler makes "positive" regulatory progress in Europe

    Oct (Shenzhen: 000069.SZ - news) 4 (Reuters) - British drugmaker Vectura said its asthma inhaler Flutiform had made favourable regulatory progress in Europe, and it can now apply for approvals through its partner. Vectura said its partner Mundipharma confirmed a "successful outcome" for the inhaler, when first assessed by the UK medicines and healthcare products regulatory agency -- which covers 18 countries across Europe. "This positive DCP outcome is an important step in the regulatory process and Mundipharma can now begin to apply for national approvals and reimbursement in the European countries covered by this procedure", Chief Executive Officer James Ward-Lilley said in a statement on Wednesday.

  • Reuters - UK Focus10 months ago

    Drugmaker Vectura warns of destocking hit, shares slide

    British drugmaker Vectura reported a doubling in first-half losses and warned full-year revenues would be hit by customers running down stocks of asthma inhaler Flutiform, sending its shares as much as 14 percent lower on Wednesday. The company, which bought rival SkyePharma (LSE: 4547152.L - news) for 441 million pounds ($575 million) in June 2016, said full-year revenues from product supplies and device sales were likely to be flat on a comparable basis with the previous year. "Although Vectura has undertaken to lower its R&D expense to compensate such that the net effect is 'broadly neutral at earnings,' we think the market may be disappointed by the implied negative change to 2017 earnings mix," they wrote in a research note, keeping a "hold" rating on the stock.

  • Reuters - UK Focus10 months ago

    Drugmaker Vectura's H1 revenue up 6 pct on rising sales of inhaled products

    Sept 6 - Vectura said revenue rose 6 percent in the first half of the year, driven by rising sales of its recently launched inhaled products and the continued weakness of sterling against a basket of its ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes